TrialJCI insight2019

Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL.

Mark B Geyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.